Get the Stockscreener App
30.41
3.58%
-1.13
Harrow Inc stock is traded at $30.41, with a volume of 331.69K.
It is down -3.58% in the last 24 hours and up +7.04% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$31.54
Open:
$31.06
24h Volume:
331.69K
Relative Volume:
0.62
Market Cap:
$1.14B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-31.68
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-2.44%
1M Performance:
+7.04%
6M Performance:
-13.30%
1Y Performance:
+71.91%
1-Day Range:
$30.01
$31.58
1-Week Range:
$30.01
$32.45
52-Week Range:
$17.46
$59.23
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
30.41 | 1.14B | 154.15M | -33.58M | -20.74M | -0.96 |
|
RGC
Regencell Bioscience Holdings Ltd
|
78.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
161.67 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Opaleye Management Inc. Adjusts Holdings in Harrow Inc. - GuruFocus
Harrow wins new Outperform at William Blair after licensing deal for pain drug - MSN
HARROW HEALTH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options - The Globe and Mail
BTIG Initiates Harrow at Buy With $62 Price Target - marketscreener.com
BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook - GuruFocus
Harrow Inc. sees $923,827 in stock sales by major shareholder - Investing.com South Africa
BTIG Initiates Coverage of Harrow (HROW) with Optimistic Outlook | HROW Stock News - GuruFocus
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy - Benzinga
HARROW HEALTH INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Harrow Health To Contact Him Directly To Discuss Their Options - The Globe and Mail
Harrow acquires U.S. commercial rights to BYQLOVI from Formosa Pharmaceuticals - MSN
Harrow (HROW) Gains Coverage with Outperform Rating Following Licensing Deal - GuruFocus
Harrow stock wins William Blair's new Outperform (HROW:NASDAQ) - Seeking Alpha
Assessing Harrow: Insights From 4 Financial Analysts - Benzinga
Lake Street Remains a Buy on Harrow Health (HROW) - The Globe and Mail
William Blair Initiates Coverage on Harrow (HROW) with Outperfor - GuruFocus
William Blair Initiates Coverage on Harrow With Outperform Rating - marketscreener.com
William Blair Initiates Outperform Rating for Harrow (HROW) | HR - GuruFocus
William Blair Initiates Outperform Rating for Harrow (HROW) | HROW Stock News - GuruFocus
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals - mx.advfn.com
Harrow (HROW) Secures Exclusive U.S. Rights for New Ophthalmic S - GuruFocus
Harrow (HROW) Secures U.S. Rights to BYQLOVI - GuruFocus
Harrow Acquires US Commercial Rights for Byqlovi From Formosa Pharmaceuticals - marketscreener.com
Harrow Acquires U.S. Commercial Rights To Byqlovi(TM) From Formosa Pharmaceuticals - marketscreener.com
HROW Signs Licensing Agreement for Exclusive U.S. Rights to Byqlovi 0.05% | HROW Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 29,262 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Shares Down 5.39% on Jun 5 - GuruFocus
Bank of America Corp DE Trims Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Millennium Management LLC Sells 101,671 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
B. Riley Issues Pessimistic Forecast for Harrow Earnings - Defense World
Insiders Favor Harrow And 2 Other Leading Growth Companies - Yahoo Finance
Harrow Inc (HROW) Shares Up 4.04% on May 30 - GuruFocus
Obituary for Douglas "Doug" A. Harrow - Schaffer Funeral Home, Inc.
Harrow: Epic Growth & Operating Leverage On Full Display (NASDAQ:HROW) - Seeking Alpha
Harrow Inc (HROW) Stock Price Down 3.78% on May 22 - GuruFocus
Deutsche Bank AG Has $3.63 Million Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
The Manufacturers Life Insurance Company Has $372,000 Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Stock Price Up 8.35% on May 16 - GuruFocus
Harrow Inc.: Opaleye management sells $150,055 in stock - Investing.com Australia
Harrow Inc.: Opaleye management sells $150,055 in stock By Investing.com - Investing.com India
Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout” - Insider Monkey
Harrow to Present at Two Investor Conferences in May - Business Wire
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock - Benzinga
Harrow Health, Inc. (NASDAQ:HROW) Q1 2025 Earnings Call Transcript - Insider Monkey
Harrow (HROW) Faces Price Target Cut Amid Q1 Earnings Miss | HRO - GuruFocus
HROW Stock Price Target Raised to $60 by Analyst | HROW Stock Ne - GuruFocus
Price T Rowe Associates Inc. MD Buys 1,428 Shares of Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow (NASDAQ:HROW) Price Target Raised to $60.00 at HC Wainwright - Defense World
Where Harrow Stands With Analysts - Benzinga
HROW Stock Update: Analyst Raises Price Target to $60 | HROW Sto - GuruFocus
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - MSN
Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... - Yahoo Finance
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):